Dr. Peter Geistlich – Pioneer and visionary

Until his death in 2014, Dr. Peter Geistlich was President of the Board of Directors at Geistlich Pharma AG. He has worked at the company since the 1950s. In the 1980s, Dr. Peter Geistlich had the vision of investing in regenerative biomaterials. For this purpose, he established a business division within the Geistlich Group and ushered in a new era. Even today, his name still stands for the quality of our products and characterises the company in the long term.


Product development with international scientists

In collaboration with international researchers – predominantly with Prof. Dr. Philip J. Boyne from the University of Loma Linda in California - Dr. Peter Geistlich did pioneering work in bone regeneration. For the first time, he freed bone material from organic components – without changing the natural microstructure and bone composition. He thus invented the bone replacement material Geistlich Bio-Oss®.

“Until today, the name of Dr. Peter Geistlich stands for the quality of our products.”
Paul Note, CEO Geistlich Pharma AG


He developed the natural collagen membrane Geistlich Bio-Gide®, which thanks to good wound healing properties facilitates a simple operation technique and fundamentally changed bone regeneration. Geistlich Pharma has remained true to the approach of science-based development in collaboration with universities and practitioners – for existing products and new developments.


Combining science with practical application

In 2003, Dr. Peter Geistlich, together with Geistlich Pharma AG, established the Osteology Foundation. His goal was to create a platform that makes science accessible to industry and practitioners, enabling it to be implemented in practice. With success: in 2013, the Osteology Foundation celebrated its 10-year anniversary during the extremely successful International Osteology Symposium in Monaco. In 2013 Dr. Peter Geistlich and Geistlich Pharma launched the American Osteo Science Foundation with the objective to establish a platform for funded and entirely independent basic and applied research for new therapy approaches and clinical treatment methods in dental medicine. Accompanying implementation of teaching to establish new knowledge is also a core issue.


Dr. Mirjam Kessler
Director Corporate Communications